Abstract
A new series of 8-halogen-4,4a,5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acids was prepared and tested for aldose reductase (ALR2) inhibitory activities. These compounds showed significant inhibitory activity against bovine lens ALR2, with the best compound 2e showing an IC50 value of 31.4 μM. The presence of the C8-substituents here studied (Cl, Br) on the thienocinnolinone scaffold caused a decrease of the inhibitory potency by a factor of about 4 with respect to the unsubstituted parent compound, while the presence of a C8-methyl group, considered in a previous paper [1] decreased the activity by a factor of about 2. Moreover, the length of the N2 alkanoic chain influences strongly the enzyme inhibitory activity. While most of the carboxylic acids ALR2 inhibitors are acetic acid derivatives, in the case of thienocinnolinone compounds, homologues higher than acetic acids showed to be more active.
Keywords: thieno[h]cinnolinone carboxylic acids, aldose reductase inhibitors, Diabetic complications
Medicinal Chemistry
Title: Thienocinnolinone Alkanoic Acid Derivatives as Aldose Reductase Inhibitors
Volume: 2 Issue: 1
Author(s): G. A. Pinna, D. Rakowitz, L. Costantino, G. E. Grella, G. Boatto, G. Murineddu, B. Asproni and A. Pau
Affiliation:
Keywords: thieno[h]cinnolinone carboxylic acids, aldose reductase inhibitors, Diabetic complications
Abstract: A new series of 8-halogen-4,4a,5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acids was prepared and tested for aldose reductase (ALR2) inhibitory activities. These compounds showed significant inhibitory activity against bovine lens ALR2, with the best compound 2e showing an IC50 value of 31.4 μM. The presence of the C8-substituents here studied (Cl, Br) on the thienocinnolinone scaffold caused a decrease of the inhibitory potency by a factor of about 4 with respect to the unsubstituted parent compound, while the presence of a C8-methyl group, considered in a previous paper [1] decreased the activity by a factor of about 2. Moreover, the length of the N2 alkanoic chain influences strongly the enzyme inhibitory activity. While most of the carboxylic acids ALR2 inhibitors are acetic acid derivatives, in the case of thienocinnolinone compounds, homologues higher than acetic acids showed to be more active.
Export Options
About this article
Cite this article as:
Pinna A. G., Rakowitz D., Costantino L., Grella E. G., Boatto G., Murineddu G., Asproni B. and Pau A., Thienocinnolinone Alkanoic Acid Derivatives as Aldose Reductase Inhibitors, Medicinal Chemistry 2006; 2 (1) . https://dx.doi.org/10.2174/157340606775197769
DOI https://dx.doi.org/10.2174/157340606775197769 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Enzyme Inhibitors
Current Bioactive Compounds Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Current Diabetes Reviews Challenges for the Treatment of Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders
Current Neuropharmacology Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews Role of Immune Cells in Diabetic Kidney Disease
Current Gene Therapy Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research RNA Interference as A Gene-Specific Approach for Molecular Medicine
Current Medicinal Chemistry Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research